Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial
- PMID: 22554931
- PMCID: PMC3361667
- DOI: 10.1016/S1474-4422(12)70091-1
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial
Abstract
Background: Previous studies have suggested that any benefits of folic acid-based therapy to lower serum homocysteine in prevention of cardiovascular events might be offset by concomitant use of antiplatelet therapy. We aimed to establish whether there is an interaction between antiplatelet therapy and the effects of folic acid-based homocysteine-lowering therapy on major vascular events in patients with stroke or transient ischaemic attack enrolled in the vitamins to prevent stroke (VITATOPS) trial.
Methods: In the VITATOPS trial, 8164 patients with recent stroke or transient ischaemic attack were randomly allocated to double-blind treatment with one tablet daily of placebo or B vitamins (2 mg folic acid, 25 mg vitamin B(6), and 500 μg vitamin B(12)) and followed up for a median 3·4 years (IQR 2·0-5·5) for the primary composite outcome of stroke, myocardial infarction, or death from vascular causes. In our post-hoc analysis of the interaction between antiplatelet therapy and the effects of treatment with B vitamins on the primary outcome, we used Cox proportional hazards regression before and after adjusting for imbalances in baseline prognostic factors in participants who were and were not taking antiplatelet drugs at baseline and in participants assigned to receive B vitamins or placebo. We also assessed the interaction in different subgroups of patients and different secondary outcomes. The VITATOPS trial is registered with ClinicalTrials.gov, number NCT00097669, and Current Controlled Trials, number ISRCTN74743444.
Findings: At baseline, 6609 patients were taking antiplatelet therapy and 1463 were not. Patients not receiving antiplatelet therapy were more likely to be younger, east Asian, and disabled, to have a haemorrhagic stroke or cardioembolic ischaemic stroke, and to have a history of hypertension or atrial fibrillation. They were less likely to be smokers and to have a history of peripheral artery disease, hypercholesterolaemia, diabetes, ischaemic heart disease, and a revascularisation procedure. Of the participants taking antiplatelet drugs at baseline, B vitamins had no significant effect on the primary outcome (488 patients in the B-vitamins group [15%] vs 519 in the placebo group [16%]; hazard ratio [HR] 0·94, 95% CI 0·83-1·07). By contrast, of the participants not taking antiplatelet drugs at baseline, B vitamins had a significant effect on the primary outcome (123 in the B-vitamins group [17%] vs 153 in the placebo group [21%]; HR 0·76, 0·60-0·96). The interaction between antiplatelet therapy and the effect of B vitamins on the primary outcome was significant after adjusting for imbalance in the baseline variables (adjusted p for interaction=0·0204).
Interpretation: Our findings support the hypothesis that antiplatelet therapy modifies the potential benefits of lowering homocysteine with B-vitamin supplementation in the secondary prevention of major vascular events. If validated, B vitamins might have a role in the prevention of ischaemic events in high-risk individuals with an allergy, intolerance, or lack of indication for antiplatelet therapy.
Funding: Australia National Health and Medical Research Council, UK Medical Research Council, Singapore Biomedical Research Council, and Singapore National Medical Research Council.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Figures
![Figure](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3361667/bin/gr1.gif)
Comment in
-
Unmasking the benefits of B vitamins in stroke prevention.Lancet Neurol. 2012 Jun;11(6):481-3. doi: 10.1016/S1474-4422(12)70094-7. Epub 2012 May 2. Lancet Neurol. 2012. PMID: 22554930 No abstract available.
-
Stroke: B vitamins show benefit in absence of antiplatelet therapy.Nat Rev Neurol. 2012 May 22;8(6):298. doi: 10.1038/nrneurol.2012.95. Nat Rev Neurol. 2012. PMID: 22614856 No abstract available.
Similar articles
-
Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis.Stroke. 2013 Aug;44(8):2232-9. doi: 10.1161/STROKEAHA.113.001886. Epub 2013 Jun 13. Stroke. 2013. PMID: 23765945 Clinical Trial.
-
B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy.Stroke. 2012 Dec;43(12):3266-70. doi: 10.1161/STROKEAHA.112.665703. Epub 2012 Oct 23. Stroke. 2012. PMID: 23093615 Clinical Trial.
-
B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.Lancet Neurol. 2010 Sep;9(9):855-65. doi: 10.1016/S1474-4422(10)70187-3. Epub 2010 Aug 3. Lancet Neurol. 2010. PMID: 20688574 Clinical Trial.
-
The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke.Cerebrovasc Dis. 2002;13(2):120-6. doi: 10.1159/000047761. Cerebrovasc Dis. 2002. PMID: 11867886 Review.
-
Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.Cochrane Database Syst Rev. 2001;(4):CD001342. doi: 10.1002/14651858.CD001342. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001342. doi: 10.1002/14651858.CD001342.pub2. PMID: 11687110 Updated. Review.
Cited by
-
Differential effect of ticagrelor versus clopidogrel by homocysteine levels on risk of recurrent stroke: a post hoc analysis of the CHANCE-2 trial.CMAJ. 2024 Feb 11;196(5):E149-E156. doi: 10.1503/cmaj.231262. CMAJ. 2024. PMID: 38346785 Free PMC article. Clinical Trial.
-
Predictive value of nutritional indices for left atrial thrombus in patients with valvular atrial fibrillation.BMC Cardiovasc Disord. 2023 Oct 27;23(1):526. doi: 10.1186/s12872-023-03493-4. BMC Cardiovasc Disord. 2023. PMID: 37891483 Free PMC article.
-
The role of homocysteine levels as a risk factor of ischemic stroke events: a systematic review and meta-analysis.Front Neurol. 2023 May 12;14:1144584. doi: 10.3389/fneur.2023.1144584. eCollection 2023. Front Neurol. 2023. PMID: 37251231 Free PMC article.
-
Serum Homocysteine Level Predictive Capability for Severity of Restenosis Post Percutaneous Coronary Intervention.Front Pharmacol. 2022 May 24;13:816059. doi: 10.3389/fphar.2022.816059. eCollection 2022. Front Pharmacol. 2022. PMID: 35685647 Free PMC article.
-
Plasma Total Homocysteine Level Is Related to Unfavorable Outcomes in Ischemic Stroke With Atrial Fibrillation.J Am Heart Assoc. 2022 May 3;11(9):e022138. doi: 10.1161/JAHA.121.022138. Epub 2022 Apr 26. J Am Heart Assoc. 2022. PMID: 35470699 Free PMC article.
References
-
- Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke. 2004;35:345–347. - PubMed
-
- Homocysteine Lowering Trialists' Collaboration Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82:806–812. - PubMed
-
- Clarke R, Halsey J, Lewington S. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010;170:1622–1631. - PubMed
-
- Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA. 2011;306:2610–2611. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical